Diagnosis and prevention of atherosclerotic cerebral infarction

CNS Spectrums

Volumn 10, Issue 7, 2005, Pages 553-564

  Weinberger, Jesse ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NORTH GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOXAZOSIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; SIMVASTATIN; TELMISARTAN; TICLOPIDINE; WARFARIN;

AFRICAN AMERICAN; ANTICOAGULANT THERAPY; AORTA ARCH; ASIAN; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CAUSE OF DEATH; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIABETES MELLITUS; DIET; DOPPLER ECHOGRAPHY; EXERCISE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIVER TOXICITY; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; META ANALYSIS; NEUROIMAGING; NEUTROPENIA; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; STENT; SYSTEMATIC REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; UNITED STATES;

EID: 22844443992     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900010208     Document Type: Review

References (112)

1. Genazzani AR, Petraglia F, Purdy RH, eds. The Brain: Source and Target for Sex Steroid I. American Heart Association. Heart Disease and Stroke Statistics-2003 Update. Dallas, Tex: American Heart Association; 2002.
2. Bogousslavsky J, Van Melle G, Regli F. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke. 1988;19:1083-1092.
3. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-1412.
4. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology. 1965;15:774-778.
5. Fisher CM, Gore I, Okabe N, White PD. Atherosclerosis of the carotid and vertebral arteries. Extracranial and intracranial. J Neuropath Exp Neurol. 1965;24:455-476.
6. Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. Stroke. 1995;26:14-20.
7. Elmore EM, Mosquera A, Weinberger J. The prevalence of asymptomatic intracranial large-vessel occlusive disease: the role of diabetes. J Neuroimaging. 2003;13:224-22.
8. Tunick PA, Culliford AT, Lamparello PJ, Kronzon I. Atheromatosis of the aortic arch as an occult source of multiple systemic emboli. Ann Intern Med. 1991;114:391-392.
9. Fuster V. Coronary artery disease: a clinical-pathological correlation. In: Fuster V, ed. Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology. Armonk, NY: Futura Publishing Co.; 1996:1-15.
10. Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, Glagov S. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res. 1983;53:502-514.
11. O'Brien ER, Schwartz SM. A new view of restenosis. In: Fuster V, ed. Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology. Armonk, NY: Futura Publishing Co.; 1996:485-505.
12. Bond MG, Barnes RW, Riley WA, et al. High-resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities (ARIC) cohort. J Neuroimaging. 1991;1:168-172.
13. Falk E. Plaque rupture with severe pre-existing coronary stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusion thrombi. Br Heart J. 1983;50:127-134.
14. Imparato AM, Riles TS, Gorstein F. The carotid bifurcation plaque: pathologic findings associated with cerebral ischemia. Stroke. 1979;10:238-245.
15. Imparato AM, Riles TS, Mintzer R, Baumann FG. The importance of hemorrhage in the relationship between gross morphologic characteristics and cerebral symptoms in 376 carotid artery plaques. Ann Surg. 1983;1979:195-203.
16. Lusby RJ, Ferrell LD, Ehrenfeld WK, Stoney RJ, Wylie EJ. Carotid plaque hemorrhage. Its role in production of cerebral ischemia. Arch Surg. 1982;117:1479-1488.
17. Reilly LM, Lusby RJ, Hughes L, Ferrell LD, Stoney RJ, Ehrenfeld WK. Carotid plaque histology using real-time ultrasonography. Clinical and therapeutic implications. Am J Surg. 1983;146:188-193.
18. Steffen CM, Gray-Weale AC, Byrne KE, Lusby RJ. Carotid artery atheroma. Ultrasound appearance in symptomatic and asymptomatic vessels. Aust NZ J Surg. 1989;59:529-534.
19. Weinberger J, Marks SJ, Gaul JJ, et al. Atherosclerotic plaque at the carotid artery bifurcation. Correlation of ultrasonographic imaging with morphology. J Ultrasound Med. 1987;6:363-366.
20. Langsfeld M, Gray-Weale AC, Lusby RJ. The role of plaque morphology and diameter reduction in the development of new symptoms in asymptomatic carotid arteries. J Vasc Surg. 1989;9:548-557.
21. Johnson JM, Kennelly MM, Decesare D, Morgan S, Sparrow A. Natural history of asymptomatic carotid plaque. Arch Surg. 1985;120:1010-1012.
22. Weinberger J, Ramos L, Ambrose JA, Fuster V. Morphologic and dynamic changes of atherosclerotic plaque at the carotid artery bifurcation: Sequential imaging by real time imaging by real time B-mode ultrasonography. J Am Coll Cardiol. 1988;12:1515-1521.
23. Moore WS, Hall AD. Importance of emboli from carotid bifurcation in pathogenesis of cerebral ischemic attacks. Arch Surg. 1970;101:708-711.
24. Mitusch R, Doherty C, Wucherpfenning H, et al. Vascular events during follow-up in patients with aortic arch atherosclerosis. Stroke. 1997;28:36-39.
25. Weinberger J, Papamitsakis N, Newfield A, Godbold J, Goldman M. Plaque morphology correlates with cerebrovascular symptoms in patients with complex aortic arch plaque. Arch Neurol. 2000;57:81-84.
26. Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo controlled trial of antidepressants. Am J Psychiatry. 2003;160:1823-1829.
27. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2444.
28. Gueyffier F, Boutitie F, Boisel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med. 1997;126:761-767.
29. Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med. 1994;121:355-362.
30. Perry HM, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465-471.
31. Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet. 1999;353:793-796.
32. Voko Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension. 1999;34:1181-1185.
33. Alex M, Baron EK, Goldenberg S, Blumenthal HT. An autopsy study of cerebrovascular accident in diabetes melilitus. Circulation. 1962;25:663-667.
34. Merimee TJ. Diabetic retinopathy. A synthesis of perspectives. N Engl J Med. 1990;322:978-983.
35. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
36. Woo J, Lam CW, Kay R, Wong AH, Teoh R, Nicholls MG. The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol. 1990;47:1174-1177.
37. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
38. Ibsen H, Lindholm LH, Pedersen OL, Dahlof B, Kjeldsen S. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study [Danish]. Ugeskr Laeger. 2003;165:459-462.
39. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
40. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491-1498.
41. Kannel WB, Wolf PA. Epidemiology of cerebrovascular disease. In Ross-Russell RW, ed. Vascular Disease of the Central Nervous System. New York, NY: Churchill Livingstone; 1983:1-24.
42. Arenillas JF, Molina CA, Chacon P, et al. High lipoprotein (a), diabetes and the extent of symptomatic intracranial atherosclerosis. Neurology. 2004;63:27-32.
43. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
44. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-235.
45. Brown BG, Zhao X-Q, Poulin D, Albers JJ. Coronary angiographic changes, lipid-lowering therapy and their relationship to clinical cardiac events. In: Fuster V, ed. Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology. Armonk, NY: Futura Publishing Co.; 1996:471-482.
46. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
47. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
48. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
49. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718
50. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
51. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90:1679-1687.
52. Crouse JR 3rd, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II) Am J Cordiol. 1995;75:455-459.
53. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-766.
54. Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002;106:2884-2887.
55. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996;334:1156-1162.
56. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
57. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87(3 suppl):II56-II65.
58. Tell GS, Howard G, McKinney WM, Toole JF. Cigarette smoking cessation and extracranial carotid atherosclerosis. JAMA. 1989;261:1178-1180.
59. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
60. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
61. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44:1175-1180.
62. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569.
63. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest. 1989;84:1134-1144.
64. Ruggeri ZM. Mechanisms of shear-induced platelet adhesion and aggregation. Thromb Haemost. 1993;70:119-123.
65. Sinzinger H, Rodrigues M, Kritz H. Radioisotopic imaging of atheroma. In: Fuster V, ed. Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology. Armonk, NY: Futura Publishing Co.; 1996:369-383.
66. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelet. I. Acetylation of a particular fraction protein. J Clin Invest. 1975;56:624-632.
67. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
68. Johnson M, Walton PL, Cotton RC, Strachan CJL. Pharmacological evaluation of ticlopidine, a novel inhibitor of platelet function. Thromb Hoemost. 1977;38:64-69.
69. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1988;321:501-507.
70. Grotta JC, Morris JW, Kamm B. Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup. Neurology. 1992;42:1111-1115.
71. Gorelick P, Richardson De J, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized clinical trial. JAMA. 2003;289:2947-2957.
72. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998;128:541-544.
73. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.
74. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
75. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
76. Fitzgerald GA. Dipyridamole. N Engl J Med. 1987;316:1247-1257.
77. Acheson J, Danta G, Hutchinson EC. Controlled trial of dipytidamole in cerebral vascular disease. Br Med J. 1969;1:614-615
78. Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group. Stroke. 1985;16:406-415.
79. European Stroke Prevention Study. ESPS Group. Stroke. 1990;21:1122-1130.
80. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
81. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
82. Hankey GJ. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care. Cerebrovasc Dis. 2004;17:11-16.
83. Weinberger J, Biscarra V, Weitzner I Jr, Sacher M. Noninvasive carotid artery testing: role in the management of patients with transient ischemic attacks. N Y State J Med. 1981;81:1463-1468.
84. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1991;325:445-453.
85. Barnett HJM, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate to severe stenosis. N Engl J Med. 1998;339:1415-1425.
86. Polak JF, Bajakian RL, O'Leary DH, Anderson MR, Donaldson MC, Jolesz FA. Detection of internal carotid artery stenosis: comparison of MR angiography, color Doppler sonography and arteriography. Radiology. 1992;182:35-40.
87. Wennberg DE, Lucas FL, Birkmeyer JD, et al. Variation in carotid endarterectomy mortality in the Medicare population. Trial hospitals, volume and patient characteristics. JAMA 1998;270:1278-1281
88. Cebul RD, Snow RJ, Pine R, Hertzer NR, Morris DG. Indications, outcomes and provider volumes for carotid endarterectomy. JAMA. 1998;279:1282-1287.
89. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995;273:1421-1428.
90. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. 2004;363:1491-1502.
91. Morris JW, Zhu CZ, Bornstein NM, Chambers BR. Vascular risks of asymptomatic carotid stenosis. Stroke. 1991;22:1485-1490.
92. Diethrich EB, Ndiaye M, Reid DB. Stenting in the carotid artery: initial experience in 110 patients. J Endovasc Surg. 1996;3:42-62.
93. Wholey MH, Wholey MH, Jarmolowski CR, Eles G, Levy D, Buecthel J. Endovascular stents for carotid artery occlusive disease. J Endovasc Surg. 1997;4:326-328.
94. Qureshi AI, Luft AR, Janardhan V, et al. Identification of patients at risk for periprocedural neurological deficits associated with carotid angioplasty and stenting. Stroke. 2000;31:376-382.
95. Alazzaz A, Thornton J, Aletich VA, Debrun GM, Austrian JI, Charbel F. intracranial percutaneous transluminal angioplasty for arteriosclerotic stenosis. Arch Neurol. 2000;57:1625-1630.
96. Malek AM, Higashida RT, Phatouros CC, et al. Stent angioplasty for cervical carotid artery stenosis in high-risk symptomatic NASCET-ineligible patients. Stroke. 2000;31:3029-3033
97. Cremonesi A, Manetti R, Setacci F, Setacci C, Castriota F. Protected carotid stenting. Clinical advantages and complications of embolic protection devices in 442 consecutive patients. Stroke. 2003;34:1936-1943.
98. Yadav J, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high risk patients. N Engl J Med. 2004;351:493-501.
99. Hilton TC, Menke D, Blackshear JL. Variable effect of anticoagulation in the treatment of severe protruding atherosclerotic debris. Am Heart J. 1994;127:1645-1647.
100. Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol. 1998;31:134-138.
101. Fredberg RS, Tunick PA, Culliform AT, et al. Disappearance of a large intraaortic mass in a patient with prior systemic embolization. Am Heart J. 1993;25(5 pt 1):1445-1447.
102. Tunick PA, Nayar AC, Goodkin GM, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol. 2002;90:1320-1325.
103. Tunick PA, Culliford AT, Lamparello PJ, Kronzon I. Atheromatosis of the aortic arch as an occult source of multiple systemic emboli. Ann Intern Med. 1991;114:391-392.
104. Geraci A, Weinberger J. Natural history of aortic arch plaque. Neurology. 2000;54:749-751.
105. Chimowitz MI, Kokkinos J, Strong J, et al. The wararin-aspirin symptomatic intracranial disease study. Neurology. 1995;45:1488-1493.
106. Caplan LR. Advances in stroke research: basic science, treatment, and clinical trial outcomes. Highlights of the 29th International Stroke Conference. Rev Neurol Dis. 2004;1:91-94.
107. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-628.
108. Gupta R, Shumacher HC, Magla S, et al. Urgent endovascular revascularization for symptomatic intracranial atherosclerotic stenosis. Neurology. 2003;61:1729-1735.
109. Chaturvedi S, Caplan LP. Angioplasty for intracranial atherosclerosis: is the treatment worse than the disease? Neurology. 2003;61:1647-1658.
110. Weinberger J, Rothlauf E, Materese E, Halperin J. Noninvasive evaluation of the extracranial carotid arteries in patients with cerebrovascular events and atrial fibrillations. Arch Int Med. 1990;150:458-460.
111. Kanter MC, Tegeler CH, Pearce LA, Weinberger J, et al. Carotid stenosis in patients with atrial fibrillation. Prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. Arch Int Med. 1994;154:1372-1377.
112. Horowitz DR, Tuhrim S, Weinberger JM, Rudolph SH. Mechanisms in lacunar infarction. Stroke. 1992;23:325-327.